RxDoctor Payments Data

Cindy Kimura, PA

Physician Assistant · Scottsdale, AZNPI 1316271208

Payments from drug & device makers

$1,297in general payments, 2019–2025

Across 35 payments — averaging $37.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$504
  • AstraZeneca$241
  • Verona Pharma, Inc.$62
  • GSK$54
  • Tersera Therapeutics LLC$41
  • Philips North America LLC$39
  • plus $356 from 14 others

What the payments were for

  • Food & beverage$1,27598%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,297 in reported general payments places this provider in the 70th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$14,189
Medicare patients
46
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide23$27,564
EliquisApixaban43$27,532
VascepaIcosapent Ethyl27$20,462
XareltoRivaroxaban16$19,647
JardianceEmpagliflozin21$17,252
GemtesaVibegron23$11,920
RybelsusSemaglutide11$11,297
JanumetSitagliptin Phos/Metformin Hcl11$7,031
Lubiprostone27$5,078
SymbicortBudesonide/Formoterol Fumarate12$3,422
Atorvastatin Calcium181$2,986
Risperidone80$2,968
Gabapentin147$2,631
Losartan Potassium120$2,611
Trazodone Hcl192$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$28$19,64716 claims
Boehringer IngelheimJardiance$15$17,25221 claims
MerckJanumet$33$7,03111 claims
AstraZenecaSymbicort$241$3,42212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →